add B'

What is claimed is

1. A solid antibiotic composition which comprises 7β-[2-(2-imino-4-thiazolin-4-yl)acetamido]-3-{1-[2-(N,N-dimethylamino)ethyl]-1H-tetrazol-5-yl}thiomethyl-3-cephem-4-carboxylic acid dihydrochloride or its hydrate and a pharmaceutically acceptable carbonic acid salt, the amount ratio of the hydrogen chloride moiety of 7β-[2-(2-imino-4-thiazolin-4-yl)acetamido]-3-{1-[2-(N,N-dimethylamino)ethyl]-1H-tetrazol-5-yl}thiomethyl-3-cephem-4-carboxylic acid dihydrochloride or its hydrate relative to the pharmaceutically acceptable carbonic acid salt being substantially 1:1 to 2 equivalents.

2. A solid antibiotic composition as claimed in Claim 1, wherein the amount ratio of the hydrogen chloride moiety relative to the pharmaceutically acceptable carbonic acid salt being substantially 1:1 to 1.4 equivalents.

3. A solid antibiotic composition as claimed in Claim 1, wherein water content of 7β-[2-(2-imino-4-thiazolin-4-yl)acetamido]-3-{1-[2-(N,N-dimethylamino)ethyl]-1H-tetrazol-5-yl}thiomethyl-3-cephem-4-carboxylic acid dihydrochloride hydrate is substantially 1 to 4 mols per mol of 7β-[2-(2-imino-4-thiazolin-4-yl)acetamido]-3-{1-[2-(N,N-dimethylamino)ethyl]-1H-tetrazol-5-yl}thiomethyl-3-cephem-4-carboxylic acid dihydrochloride part.

4. A solid antibiotic composition as claimed in Claim 1, wherein the water content is substantially 1 to 2 mols per mol

of 7β-[2-(2-imino-4-thiazolin-4-yl)acetamido]-3-{1-[2-(N,N-dimethylamino)ethyl]-1H-tetrazol-5-yl}thiomethyl-3-cephem-4-carboxylic acid dihydrochloride part.

5. A solid antibiotic composition as claimed in any one of Claims 1 to 4, wherein the pharmaceutically acceptable carbonic acid salt is sodium carbonate.

6. A solid antibiotic composition as claimed in any one of claims 1 to 4, wherein the pharmaceutically acceptable carbonic acid salt is sodium hydrogen carbonate.

7. A solid antibiotic composition, which comprises 7β-[2-(2-imino-4-thiazolin-4-yl)acetamido]-3-{1-[2-(N,N-dimethylamino)-ethyl]-1H-tetrazol-5-yl}thiomethyl-3-cephem-4-carboxylic acid dihydrochloride hydrate, of which water content is substantially 1 to 2 mols per mol of 7β-[2-(2-imino-4-thiazolin-4-yl)acetamido]-3-1-[2-(N,N-dimethylamino)ethyl]-1H-tetrazol-5-yl}thiomethyl-3-cephem-4-carboxylic acid dihydrochloride part, and sodium hydrogen carbonate, the amount of sodium hydrogen carbonate being substantially 2 to 4 mols per mol of said hydrate.

8. A method for producing a solid antibiotic composition as claimed in any one of Claims 1 to 7, which comprises mixing 7β-[2-(2-imino-4-thiazolin-4-yl)acetamido]-3-{1-[2-(N,N-dimethylamino)ethyl]-1H-tetrazol-5-yl}thiomethyl-3-cephem-4-carboxylic acid dihydrochloride or its hydrate and a pharmaceutically acceptable carbonic acid salt.

9. A method as claimed in Claim 8, wherein the pharmaceutically acceptable carbonic acid salt is sodium hydrogen carbonate.

10. A method as claimed in Claim 8, wherein the pharmaceutically acceptable carbonic acid salt is sodium carbonate.

11. A vacuum-sealed vial, which contains a solid antibiotic composition as claimed in any one of Claims 1 to 7, the pressure in the vial being in the range of from 0 to 300 mmHg.

12. A vacuum-sealed vial as claimed in Claim 11, wherein the vial contains sodium hydrogen carbonate as the pharmaceutically acceptable carbonic acid salt.

13. A vacuum-sealed vial as claimed in Claim 12, wherein the vial contains sodium carbonate as the pharmaceutically acceptable carbonic acid salt.

14. A method for preparing a vacuum-sealed vial as claimed in any one of Claims 11 to 13, which comprises packing a solid antibiotic composition as claimed in any one of Claims 1 to 7 into a vial and vacuum-sealing the vial at a pressure in the range of from 0 to 300 mmHg.